logo-loader
RNS
viewSynairgen PLC

Synairgen plc - Directors' Share Purchase

RNS Number : 4335F
Synairgen plc
12 November 2015
 

 

PRESS RELEASE

12 November 2015

SYNAIRGEN PLC

("Synairgen" or "the Company")

 

Directors' Share Purchase

 

Southampton, UK, 12 November 2015: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, was informed that on 11 November 2015 the following Directors acquired ordinary shares of 1p each in the Company ("Ordinary Shares") at a price of 23p per Ordinary Share as follows:

 



Interest before purchase


Interest after purchase

Director

Title

Number of Ordinary Shares

Number of Ordinary Shares acquired

Number of Ordinary Shares

% of total

issued share capital

Richard Marsden

CEO

110,972

43,460

154,432

0.17%

Dr Philip Monk

CSO

161,710

21,729

183,439

0.20%

John Ward

FD

243,912

32,594

276,506

0.30%

Simon Shaw (Note 1)

Chairman

1,408,879

65,217

1,474,096

1.61%

 

Note 1 Simon Shaw's shareholding includes 105,516 Ordinary Shares held in his pension plan.

 

 

 

 

ENDS

 

For further information, please contact:

 

Synairgen plc

Richard Marsden, Chief Executive Officer

John Ward, Finance Director

Tel: + 44 (0) 23 8051 2800

 

finnCap

Geoff Nash, James Thompson (Corporate Finance)

Stephen Norcross, Simon Johnson (Corporate Broking)

Tel: + 44 (0) 20 7220 0500

 

Consilium Strategic Communications (Financial Media and Investor Relations)

Mary-Jane Elliott / Jessica Hodgson / Laura Thornton

[email protected]

Tel: +44 (0) 20 3709 5701

 

Notes for Editors

 

About Synairgen 

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on asthma, COPD and severe lung disease, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease. Leveraging its scientific and clinical facilities at Southampton General Hospital, the Company uses in vitro and ex vivo models to progress opportunities into clinical development. The BioBank of human samples is used in these models to increase confidence in the likelihood of successful drug development. Core to Synairgen's business strategy is the realisation of value via licensing transactions - validated in 2014 by the SNG001 agreement formed with AstraZeneca. Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com 

 

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSGGGBCGUPAPPG

Quick facts: Synairgen PLC

Price: 34.5

Market: AIM
Market Cap: £51.55 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Synairgen PLC pleased with further positive data from lead COPD drug

Richard Marsden, chief executive of Synairgen plc (LON:SYN), tells Proactive's Andrew Scott data from the ongoing phase II study of their SNG001 drug suggests it's having the desired effect in boosting the antiviral defences of chronic obstructive pulmonary disease (COPD)...

on 28/6/18